Renaissance Technologies LLC Reduces Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

Renaissance Technologies LLC cut its stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 14.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 757,075 shares of the company's stock after selling 127,197 shares during the period. Renaissance Technologies LLC owned about 1.07% of Nkarta worth $1,885,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of Nkarta by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company's stock valued at $5,294,000 after purchasing an additional 33,927 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Nkarta by 252.1% in the third quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company's stock valued at $4,806,000 after acquiring an additional 761,349 shares during the period. Franklin Resources Inc. acquired a new stake in shares of Nkarta in the third quarter valued at approximately $151,000. Wellington Management Group LLP increased its holdings in shares of Nkarta by 4.1% in the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock valued at $561,000 after acquiring an additional 8,883 shares during the period. Finally, State Street Corp increased its holdings in shares of Nkarta by 1.4% in the 3rd quarter. State Street Corp now owns 1,098,062 shares of the company's stock valued at $4,963,000 after acquiring an additional 15,569 shares during the period. Institutional investors and hedge funds own 80.54% of the company's stock.

Nkarta Stock Down 3.0 %

NASDAQ NKTX traded down $0.06 during trading hours on Tuesday, hitting $1.95. 659,716 shares of the stock were exchanged, compared to its average volume of 1,091,037. The company has a market cap of $138.37 million, a price-to-earnings ratio of -1.04 and a beta of 0.83. Nkarta, Inc. has a 12-month low of $1.31 and a 12-month high of $8.33. The stock has a 50-day moving average of $1.76 and a 200 day moving average of $2.37.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. On average, equities research analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Nkarta in a research note on Thursday, March 27th. Needham & Company LLC reiterated a "buy" rating and set a $11.00 target price on shares of Nkarta in a research note on Wednesday, April 9th. Finally, Stifel Nicolaus dropped their price target on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $14.86.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.